Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2MO prostatic adenocarcinoma

Background. Hepatocellular carcinoma (HCC) is one of the most common malignant cancers with a poor prognosis. Several commonly investigated immunohistochemical markers in resected HCC have potential prognostic value, but the prognostic utility of p53 expression in HCC has remained elusive. Aim. To evaluate the prognostic value of p53 and p53 phosphorylation at serine 15 (p53 Ser15-P) in patients with HCC. Methods. Surgically resected tumors from 199 HCC patients were analyzed for p21, p53, p53 Ser15-P, and proliferating cell nuclear antigen (PCNA) expression using immunohistochemistry. Results. Stratifying by the expression of p53 Ser15-P (P = 0.016), but not by p53 (P = 0.301), revealed significantly different survival outcomes in patients with HCC. Moreover, our analysis demonstrated that patients who were PCNA-positive and p53 Ser15-P–negative had significantly worse survival outcomes (P = 0.001) than patients who were PCNA-positive and p53 Ser15-P–positive. Conclusions. P53 Ser15-P is associated with poor outcomes in patients with HCC, and this prognostic marker is useful for predicting the survival of patients with PCNA-positive HCC.

Download Full-text

Proliferating cell nuclear antigen in prostatic adenocarcinoma: Correlation with established prognostic indicators

Urology ◽

10.1016/0090-4295(94)90181-3 ◽

1994 ◽

Vol 43 (5) ◽

pp. 660-666 ◽

Cited By ~ 11

Author(s):

Susan E. Spires ◽

C. Darrell Jennings ◽

Evelyn R. Banks ◽

David P. Wood ◽

Diane D. Davey ◽

...

Keyword(s):

Proliferating Cell Nuclear Antigen ◽

Prostatic Adenocarcinoma ◽

Nuclear Antigen ◽

Prognostic Indicators ◽

Proliferating Cell

Download Full-text

The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma

Sao Paulo Medical Journal ◽

10.1590/s1516-31802004000300009 ◽

2004 ◽

Vol 122 (3) ◽

pp. 124-127 ◽

Cited By ~ 7

Author(s):

Gilvan Neiva Fonseca ◽

Miguel Srougi ◽

Katia Ramos Moreira Leite ◽

Luciano João Nesrallah ◽

Valdemar Ortiz

Keyword(s):

Gene Expression ◽

Prostate Cancer ◽

Proliferating Cell Nuclear Antigen ◽

Proliferative Activity ◽

Tumor Volume ◽

Tumor Stage ◽

Nuclear Antigen ◽

Prognostic Parameters ◽

P53 Expression ◽

Proliferating Cell

CONTEXT: Prostate cancer is the most frequent solid genitourinary neoplasm in men. Involvement of several genes has been described in the promotion and progression of prostate carcinoma. OBJECTIVE: To study the expression of the oncogenes HER2/neu and BCL2, tumor suppressor gene p53 and the tumor proliferation rate in 150 radical prostatectomy specimens, in order to define their role as prognostic parameters in localized prostate cancer. TYPE OF STUDY: Prospective study. SETTING: Universidade Federal de São Paulo and Hospital Sírio Libanês, Sao Paulo PARTICIPANTS: One hundred and fifty men who were submitted to radical prostatectomy between August 1997 and August 1998, for localized prostate cancer. MAIN MEASUREMENTS: All specimens underwent evaluation in their entirety, to determine tumor volume percentage, tumor extent and Gleason score. Immunohistochemistry was performed to determine gene expression using anti- HER2/neu, BCL2 and p53 antibodies, and proliferating cell nuclear antigen. The chi-squared test was used for correlation between gene expression, proliferative activity and histological variables. RESULTS: Thirty percent of the cases were p53 positive. There was positive correlation between p53 expression and tumor stage. The p53 expression was 22.9% and 42.6% for pT2 and pT3 tumors, respectively (p = 0.01). Expression of HER2/neu, BCL2 and proliferating cell nuclear antigen was identified in 66%, 23% and 43% of patients, respectively. There was no correlation between these three parameters and tumor volume, Gleason score or tumor stage. CONCLUSION: One-third of prostate adenocarcinomas express p53 protein, and this characteristic is related to tumor stage. HER2/neu is frequently expressed in prostate carcinomas, with no correlation with histological parameters. BCL2 is rarely expressed, and together with proliferative activity has no relationship with prognostic pathological variables in these neoplasms.

Download Full-text